Novartis said it presented its latest data on oncology at the recent 53rd annual meeting of the American Society of Clinical Oncology in Chicago.
Novartis said in a release it also will highlight its newest data in its oncology portfolio at the 14th International Conference on Malignant Lymphoma on June 14-17 in Lugano, Switzerland, and at the 22nd annual Congress of the European Hematology Association on June 22-25 in Madrid.
Novartis said in the release that over 75 of its abstracts have been accepted, and its data will cover research spanning 34 compounds in breast and lung cancers, melanoma, leukemia and other blood disorders, and myeloproliferative neoplasms.
Novartis said data covered includes updates on Kisqali in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer and updates on MONALEESA-2, a Phase 3 trial of First-Line Ribociclib + Letrozole in hormone receptor-positive, HER2-negative, advanced breast cance.
“Our presence at key medical congresses this year is marked by our innovation in targeted therapies and immuno-oncology in difficult to treat cancers,” Bruno Strigini, CEO of Novartis Oncology, said in the release. “We are particularly excited to show the first data from the JULIET trial, which evaluates the use of CTL019 in relapsed/refractory diffuse large B-cell lymphoma. These results, along with the data that led to our filing for CTL019 in relapsed/refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia, demonstrate our commitment to research in this area.”
